Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaBidirectional functions of arsenic as a carcinogen and an anti-cancer agent in human squamous cell carcinomap73 as a pharmaceutical target for cancer therapyImprinted genes and the environment: links to the toxic metals arsenic, cadmium, lead and mercury.Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview).Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions.The role of p73 in hematological malignancies.MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexOvercoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignanciesThe TP73 complex network: ready for clinical translation in cancer?p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death.Barium inhibits arsenic-mediated apoptotic cell death in human squamous cell carcinoma cells.Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells.Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.Abrus agglutinin promotes irreparable DNA damage by triggering ROS generation followed by ATM-p73 mediated apoptosis in oral squamous cell carcinoma.Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.Transplantation for Childhood Acute Lymphoblastic Leukemia
P2860
Q24605527-90C60B93-F3E8-4044-8D75-1C4B421C7654Q28538682-ED94C9AE-F9B5-44B3-BF00-24418D7EDC4FQ28611414-41F9CB8A-87CB-4FC3-ACF6-A95BEAEA8CC4Q33891724-B7661C46-EF45-4648-93F1-0A2CB0C72027Q35155855-89C0C5F8-0E3E-4A63-99C3-902DF2B1879BQ36244173-DDC4BE78-7611-4C29-8AB0-C444F2A7FFEFQ36422865-CEFBD342-4CC0-4ECF-BA9A-1F51AA57AAA7Q36706340-856428E5-E4C1-451C-8678-2622B17970F7Q36812355-FFC068BA-378F-4882-8E83-DBDD058C45C7Q38126476-2FB5EF53-FA5A-4ABB-9668-434B0156B81CQ38579148-6908CC9C-42B2-4A80-B8ED-57172F6A44BEQ39360429-207C3220-E722-4E99-893B-AA031D386754Q40169850-4B995C40-497C-461B-A9CB-2E1FF96AC135Q40493341-4F533F25-BDD0-4299-B637-BD6ADB5B4F76Q46360893-21120F21-48AA-4E1C-A110-D731337BCDD9Q48048274-8834CCFF-53AE-4B41-97CC-3EFC642C925CQ59094157-BE284E30-E0C9-49F7-9401-0D976F5C2849
P2860
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Treatment with arsenic trioxid ...... tic pathway in leukemia cells.
@ast
Treatment with arsenic trioxid ...... tic pathway in leukemia cells.
@en
Treatment with arsenic trioxide
@nl
type
label
Treatment with arsenic trioxid ...... tic pathway in leukemia cells.
@ast
Treatment with arsenic trioxid ...... tic pathway in leukemia cells.
@en
Treatment with arsenic trioxide
@nl
prefLabel
Treatment with arsenic trioxid ...... tic pathway in leukemia cells.
@ast
Treatment with arsenic trioxid ...... tic pathway in leukemia cells.
@en
Treatment with arsenic trioxide
@nl
P50
P1433
P1476
Treatment with arsenic trioxid ...... otic pathway in leukemia cells
@en
P2093
Antonio Bonati
P304
P356
10.1182/BLOOD-2003-08-2743
P407
P577
2004-03-18T00:00:00Z